Tag: ASX: PAB)
BioCina launches manufacturing program for Patrys’ injectable delirium therapy
BioCina Pty Ltd, a global Contract Development and Manufacturing Organisation (CDMO), has launched a comprehensive manufacturing program for RLS-2201, a proprietary injectable formulation of Quetiapine being developed by Patrys Ltd (ASX: PAB) for the acute treatment of delirium in intensive care.
Featured Article
Modular switchgear built for faster, verified panel builds
As switchboard builders face tighter programmes and increasing scrutiny around compliance, the way enclosure, busbar and separation concepts work together has a direct impact on build time and verification effort.
